Table 2.
Clinically significant exacerbations, by baseline characteristic subgroup
| Odds ratio, mepolizumab/placebo (95% CI) | Number of patients | ||
|---|---|---|---|
| Mepolizumab | Placebo | ||
| Annualised rate of exacerbations requiring an ED visit/hospitalisation | |||
| Age at asthma onset | |||
| ITT population | 0.36 (0.20, 0.67) | 468 | 468 |
| < 18 years | 0.23 (0.08, 0.69) | 132 | 122 |
| 18–< 40 years | 0.21 (0.05, 0.83) | 173 | 172 |
| ≥ 40 years | 0.51 (0.19, 1.35) | 162 | 174 |
| Lung function | |||
| ITT population | 0.36 (0.20, 0.67) | 468 | 468 |
| ≤ 60% predicted FEV1 | 0.41 (0.19, 0.86) | 245 | 244 |
| > 60–80% predicted FEV1 | Non-est* | n/a | n/a |
| ≥ 80% predicted FEV1 | Non-est* | n/a | n/a |
| % patients with no clinically significant exacerbations | |||
| Age at asthma onset | |||
| ITT population | 3.03 (2.25, 4.07) | 468 | 468 |
| < 18 years | 2.97 (1.67, 5.26) | 132 | 122 |
| 18–< 40 years | 3.19 (1.90, 5.36) | 173 | 172 |
| ≥ 40 years | 3.32 (1.98, 5.55) | 162 | 174 |
| Lung function | |||
| ITT population | 3.03 (2.25, 4.07) | 468 | 468 |
| ≤ 60% predicted FEV1 | 2.67 (1.79, 3.98) | 245 | 244 |
| > 60–80% predicted FEV1 | 3.18 (1.92, 5.28) | 177 | 177 |
| ≥ 80% predicted FEV1 | 4.90 (1.54, 15.62) | 46 | 47 |
CI confidence interval, ED emergency department, FEV1 forced expiratory volume in 1 s, ITT intent-to-treat, n/a not applicable, non-est non-estimable
aThe odds ratio was non-estimable for this subgroup owing to insufficient data to perform modelling